Inhaled insulin developer Dance Biopharm has announced the appointment of former Novoclem Pharmaceuticals President and CEO Anne Whitaker as a Director and CEO as of October 1st, 2018. In addition to founding and heading up inhaled drug developer Novoclem, Whitaker has also held executive positions at Bausch Health, Synta Pharmaceuticals, Sanofi, and GSK.
Whitaker commented, “I am extremely excited to be joining Dance during this critical stage of development of its novel inhaled insulin therapy, Dance 501. Upon approval, I believe Dance 501 will be transformative for diabetes patients around the world who desperately need improvement in managing their disease and are avoiding use of insulin due to their fear and dislike of injections.”
Dance Biopharm Chairman and Chief Science Officer John Patton said, “As we transition into late stage development and prepare for commercialization of our lead clinical asset, Dance 501, we need a CEO with a depth of successful commercial experience in the diabetes market. Anne brings extensive commercial experience and has worked with branded diabetes pharmaceutical products at all stages of the product life cycle. I am confident we will benefit from her experience, insight and leadership.”
Read the Dance Biopharm press release.
